SERM-3339

Drug Profile

SERM-3339

Alternative Names: 3339

Latest Information Update: 03 Jul 2002

Price : $50

At a glance

  • Originator Aventis
  • Class Osteoporosis therapies
  • Mechanism of Action Selective estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Postmenopausal osteoporosis

Most Recent Events

  • 18 Jun 2002 Discontinued - Phase-II for Postmenopausal osteoporosis prevention in Europe (unspecified route)
  • 18 Jun 2002 Discontinued - Phase-II for Postmenopausal osteoporosis treatment in Europe (unspecified route)
  • 23 May 2000 Phase-II clinical trials for Postmenopausal osteoporosis treatment in Europe (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top